{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:48:20Z","timestamp":1761490100172},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"e1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,1]]},"abstract":"<jats:p>Objectives: Clinical guidelines recommending the use of myeloid growth factors are largely based on the prescribed chemotherapy regimen. The guidelines suggest that oncologists consider patient-specific characteristics when prescribing granulocyte-colony stimulating factor (G-CSF) prophylaxis; however, a mechanism to quantify individual patient risk is lacking. Readily available electronic health record (EHR) data can provide patient-specific information needed for individualized neutropenia risk estimation. An evidence-based, individualized neutropenia risk estimation algorithm has been developed. This study evaluated the automated extraction of EHR chemotherapy treatment data and externally validated the neutropenia risk prediction model.<\/jats:p>\n               <jats:p>Materials and Methods: A retrospective cohort of adult patients with newly diagnosed breast, colorectal, lung, lymphoid, or ovarian cancer who received the first cycle of a cytotoxic chemotherapy regimen from 2008 to 2013 were recruited from a single cancer clinic. Electronically extracted EHR chemotherapy treatment data were validated by chart review. Neutropenia risk stratification was conducted and risk model performance was assessed using calibration and discrimination.<\/jats:p>\n               <jats:p>Results: Chemotherapy treatment data electronically extracted from the EHR were verified by chart review. The neutropenia risk prediction tool classified 126 patients (57%) as being low risk for febrile neutropenia, 44 (20%) as intermediate risk, and 51 (23%) as high risk. The model was well calibrated (Hosmer-Lemeshow goodness-of-fit test\u2009=\u20090.24). Discrimination was adequate and slightly less than in the original internal validation (c-statistic 0.75 vs 0.81).<\/jats:p>\n               <jats:p>Conclusion: Chemotherapy treatment data were electronically extracted from the EHR successfully. The individualized neutropenia risk prediction model performed well in our retrospective external cohort.<\/jats:p>","DOI":"10.1093\/jamia\/ocw131","type":"journal-article","created":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T02:48:51Z","timestamp":1474080531000},"page":"e-e","source":"Crossref","is-referenced-by-count":17,"title":["Predicting neutropenia risk in patients with cancer using electronic data"],"prefix":"10.1093","volume":"24","author":[{"given":"Pamala A","family":"Pawloski","sequence":"first","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota, USA"},{"name":"Health Care Systems Research Network\/National Cancer Institute Cancer Research Network, USA"},{"name":"Regions Hospital Cancer Care Center, St. Paul, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avis J","family":"Thomas","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl","family":"Kane","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Vazquez-Benitez","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Regions Hospital Cancer Care Center, St. Paul, Minnesota, USA"},{"name":"Cancer Center of Western Wisconsin, New Richmond, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary H","family":"Lyman","sequence":"additional","affiliation":[{"name":"Hutchinson Institute for Cancer Outcomes Research, Seattle, Washington, USA"},{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"},{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,9,16]]},"reference":[{"key":"2020110612435102800_ocw131-B1"},{"key":"2020110612435102800_ocw131-B2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","article-title":"Epidemiology of febrile neutropenia","volume":"1","author":"Lyman","year":"2003","journal-title":"Supportive Cancer Therapy."},{"key":"2020110612435102800_ocw131-B3","volume-title":"National Comprehensive Cancer Network, V1","author":"Myeloid Growth Factors","year":"2016"},{"key":"2020110612435102800_ocw131-B4","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003189.pub2","article-title":"Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma","volume":"3","author":"Bohlius","year":"2004","journal-title":"Cochrane Database Syst Rev."},{"key":"2020110612435102800_ocw131-B5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-147-6-200709180-00010","article-title":"Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection","volume":"147","author":"Sung","year":"2007","journal-title":"Ann Intern Med."},{"key":"2020110612435102800_ocw131-B6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-11-404","article-title":"Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis","volume":"11","author":"Cooper","year":"2011","journal-title":"BMC Cancer."},{"key":"2020110612435102800_ocw131-B7","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol."},{"key":"2020110612435102800_ocw131-B8","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","article-title":"The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Wang","year":"2015","journal-title":"Supportive Care Cancer."},{"key":"2020110612435102800_ocw131-B9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/10428199709114168","article-title":"Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte","volume":"25","author":"Gisselbrecht","year":"1997","journal-title":"Leukemia Lymphoma."},{"key":"2020110612435102800_ocw131-B10","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1200\/JCO.2004.00.7955","article-title":"Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study","volume":"23","author":"Timmer-Bonte","year":"2005","journal-title":"J Clin Oncol."},{"key":"2020110612435102800_ocw131-B11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","article-title":"Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy","volume":"29A","author":"Trillet-Lenoir","year":"1993","journal-title":"Eur J Cancer."},{"key":"2020110612435102800_ocw131-B12","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol."},{"key":"2020110612435102800_ocw131-B13","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.1995.13.10.2629","article-title":"Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity","volume":"13","author":"Bui","year":"1995","journal-title":"J Clin Oncol."},{"key":"2020110612435102800_ocw131-B14","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.1995.13.7.1564","article-title":"Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer","volume":"13","author":"Chevallier","year":"1995","journal-title":"J Clin Oncol."},{"key":"2020110612435102800_ocw131-B15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med."},{"key":"2020110612435102800_ocw131-B16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00000421-200008000-00017","article-title":"Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study","volume":"23","author":"Gatzemeier","year":"2000","journal-title":"Am J Clin Oncol."},{"key":"2020110612435102800_ocw131-B17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00000421-199606000-00004","article-title":"Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study","volume":"19","author":"Muhonen","year":"1996","journal-title":"Am J Clin Oncol."},{"key":"2020110612435102800_ocw131-B18","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1182\/blood-2002-10-3238","article-title":"CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial","volume":"101","author":"Osby","year":"2003","journal-title":"Blood"},{"key":"2020110612435102800_ocw131-B19","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.V80.6.1430.1430","article-title":"Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial","volume":"80","author":"Pettengell","year":"1992","journal-title":"Blood."},{"key":"2020110612435102800_ocw131-B20","first-page":"3974","article-title":"Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma","volume":"89","author":"Zinzani","year":"1997","journal-title":"Blood."},{"key":"2020110612435102800_ocw131-B21","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol."},{"key":"2020110612435102800_ocw131-B22","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","article-title":"Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review","volume":"28","author":"Lyman","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020110612435102800_ocw131-B23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/jnci\/djr152","article-title":"Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes","volume":"103","author":"Potosky","year":"2011","journal-title":"J Natl Cancer Inst."},{"key":"2020110612435102800_ocw131-B24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1200\/JOP.2014.002717","article-title":"Baseline Estimates of Adherence to American Society of Clinical Oncology\/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health Insurer","volume":"11","author":"Ramsey","year":"2015","journal-title":"J Oncol Pract."},{"key":"2020110612435102800_ocw131-B25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JOP.2012.000662","article-title":"Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic","volume":"9","author":"Waters","year":"2013","journal-title":"J Oncol Pract."},{"key":"2020110612435102800_ocw131-B26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1078155215585188","article-title":"Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients","volume":"22","author":"Pawloski","year":"2016","journal-title":"J Oncol Pharm Pract."},{"key":"2020110612435102800_ocw131-B27","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.6004\/jnccn.2015.0014","article-title":"Management of chemotherapy-induced neutropenia: measuring quality, cost, and value","volume":"13","author":"Dinan","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"key":"2020110612435102800_ocw131-B28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JOP.2014.001492","article-title":"Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors","volume":"11","author":"Weycker","year":"2015","journal-title":"J Oncol Pract."},{"key":"2020110612435102800_ocw131-B29","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/annonc\/mdv619","article-title":"Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis","volume":"27","author":"Truong","year":"2016","journal-title":"Ann Oncol."},{"key":"2020110612435102800_ocw131-B30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1078155215603229","article-title":"Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle","volume":"22","author":"Li","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"2020110612435102800_ocw131-B31","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cncr.25691","article-title":"Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer."},{"key":"2020110612435102800_ocw131-B32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jncimonographs\/lgi033","article-title":"Building a virtual cancer research organization","volume":"35","author":"Hornbrook","year":"2005","journal-title":"J Natl Cancer Inst Monogr."},{"key":"2020110612435102800_ocw131-B33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/MLR.0b013e3181a7e569","article-title":"Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: implications for future research","volume":"47","author":"Aiello Bowles","year":"2009","journal-title":"Med Care."},{"key":"2020110612435102800_ocw131-B34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.lungcan.2012.09.008","article-title":"Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network","volume":"78","author":"Ritzwoller","year":"2012","journal-title":"Lung Cancer."},{"key":"2020110612435102800_ocw131-B35","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1097\/MLR.0b013e31824def85","article-title":"Validation of electronic data on chemotherapy and hormone therapy use in HMOs","volume":"51","author":"Ritzwoller","year":"2013","journal-title":"Med Care."},{"key":"2020110612435102800_ocw131-B36","first-page":"1049","article-title":"The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration","volume":"2","author":"Ross","year":"2014","journal-title":"EGEMS (Wash DC)."},{"key":"2020110612435102800_ocw131-B37","author":"Strategic Management Plan","year":"2015"},{"key":"2020110612435102800_ocw131-B38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"2020110612435102800_ocw131-B39","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/sim.1844","article-title":"Validation and updating of predictive logistic regression models: a study on sample size and shrinkage","volume":"23","author":"Steyerberg","year":"2004","journal-title":"Stats Med."},{"key":"2020110612435102800_ocw131-B40","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"1998"},{"key":"2020110612435102800_ocw131-B41","doi-asserted-by":"crossref","DOI":"10.1002\/0471722146","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2000","edition":"2nd ed."},{"key":"2020110612435102800_ocw131-B42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J Natl Compr Canc Netw."},{"key":"2020110612435102800_ocw131-B43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann Hematol."},{"key":"2020110612435102800_ocw131-B44","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00520-008-0430-4","article-title":"Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study","volume":"16","author":"Pettengell","year":"2008","journal-title":"Supportive Care Cancer."},{"key":"2020110612435102800_ocw131-B45","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1002\/cncr.24560","article-title":"Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy","volume":"115","author":"Shayne","year":"2009","journal-title":"Cancer."},{"key":"2020110612435102800_ocw131-B46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-008-0018-1","article-title":"Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients","volume":"114","author":"Chirivella","year":"2009","journal-title":"Breast Cancer Res Treat."},{"key":"2020110612435102800_ocw131-B47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2407-11-131","article-title":"Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short- and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer: a pooled analysis","volume":"11","author":"Loibl","year":"2011","journal-title":"BMC Cancer."},{"key":"2020110612435102800_ocw131-B48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.critrevonc.2011.04.010","article-title":"Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer","volume":"81","author":"Lyman","year":"2012","journal-title":"Critical Rev Oncol\/Hematol."},{"key":"2020110612435102800_ocw131-B49","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2011.05.023","article-title":"Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer","volume":"122","author":"Fauci","year":"2011","journal-title":"Gynecol Oncol."},{"key":"2020110612435102800_ocw131-B50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol Oncol."},{"key":"2020110612435102800_ocw131-B51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.12.019","article-title":"Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer","volume":"66","author":"Luciani","year":"2009","journal-title":"Lung Cancer"},{"key":"2020110612435102800_ocw131-B52","first-page":"678","article-title":"Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer","volume":"16","author":"Ramsey","year":"2010","journal-title":"Am J Manag Care."},{"key":"2020110612435102800_ocw131-B53","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2012.42.8375","article-title":"American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology","volume":"30","author":"Schnipper","year":"2012","journal-title":"J Clin Oncol."},{"key":"2020110612435102800_ocw131-B54","first-page":"1153","article-title":"Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? Cancer Med","volume":"4","author":"Lyman","journal-title":"2015"},{"key":"2020110612435102800_ocw131-B55","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/sim.6787","article-title":"Sample size considerations for the external validation of a multivariable prognostic model: a resampling study","volume":"35","author":"Collins","year":"2016","journal-title":"Stats Med."}],"container-title":["Journal of the American Medical Informatics Association"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jamia\/article-pdf\/24\/e1\/e\/34149360\/ocw131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jamia\/article-pdf\/24\/e1\/e\/34149360\/ocw131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T18:16:15Z","timestamp":1604686575000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jamia\/article\/24\/e1\/e\/2631513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,16]]},"references-count":55,"journal-issue":{"issue":"e1","published-online":{"date-parts":[[2016,9,16]]},"published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jamia\/ocw131","relation":{},"ISSN":["1067-5027","1527-974X"],"issn-type":[{"value":"1067-5027","type":"print"},{"value":"1527-974X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,4]]},"published":{"date-parts":[[2016,9,16]]}}}